ChiCTR2400081914 版本V1.0 版本创建时间2024/03/15 08:43:02 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400081914 

最近更新日期:

Date of Last Refreshed on:

2024-03-15 08:42:39 

注册时间:

Date of Registration:

2024-03-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于微量元素及维生素A/D探究复合益生菌对孤独症谱系障碍儿童胃肠及行为问题的影响

Public title:

Effect of complex probiotics on gastrointestinal and behavioral problems in children with autism spectrum disorder based on trace elements and vitamin A/D

注册题目简写:

益生菌对孤独症儿童胃肠及行为问题的影响

English Acronym:

Effects of probiotics on gut and behavioral problems in children with autism

研究课题的正式科学名称:

基于微量元素及维生素A/D探究复合益生菌对孤独症谱系障碍儿童胃肠及行为问题的影响

Scientific title:

Effect of complex probiotics on gastrointestinal and behavioral problems in children with autism spectrum disorder based on trace elements and vitamin A/D

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨晓蕾 

研究负责人:

杨晓蕾 

Applicant:

Xiaolei Yang 

Study leader:

Xiaolei Yang 

申请注册联系人电话:

Applicant telephone:

+86 182 0462 7365

研究负责人电话:

Study leader's
telephone:

+86 182 0462 7365

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yxl0517@qmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

yxl0517@qmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

齐齐哈尔市建华区卜奎北大街333号部系楼B区101B

研究负责人通讯地址:

齐齐哈尔市建华区卜奎北大街333号部系楼B区101B

Applicant address:

101B, Building B, 333 Bukui North Street, Jianhua District, Qiqihar City

Study leader's address:

101B, Building B, 333 Bukui North Street, Jianhua District, Qiqihar City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

齐齐哈尔医学院

Applicant's institution:

Qiqihar Medical University

研究负责人所在单位:

齐齐哈尔医学院

Affiliation of the Leader:

Qiqihar Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(齐)伦审[2024] 1号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

齐齐哈尔医学院伦理委员会

Name of the ethic committee:

Qiqihar Medical University Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2024-01-08 00:00:00

伦理委员会联系人:

刘洋

Contact Name of the ethic committee:

Yang Liu

伦理委员会联系地址:

齐齐哈尔医学院行政楼1701

Contact Address of the ethic committee:

Qiqihar Medical University Administration Building 1701

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 452 266 3701

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

齐齐哈尔医学院

Primary sponsor:

Qiqihar Medical University

研究实施负责(组长)单位地址:

齐齐哈尔市建华区卜奎北大街333号部系楼B区101B

Primary sponsor's address:

101B, Building B, 333 Bukui North Street, Jianhua District, Qiqihar City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

黑龙江

市(区县):

齐齐哈尔市

Country:

China

Province:

Heilongjiang

City:

Qiqihar

单位(医院):

齐齐哈尔医学院

具体地址:

齐齐哈尔市建华区卜奎北大街333号部系楼B区101B

Institution
hospital:

Qiqihar Medical University

Address:

101B, Building B, 333 Bukui North Street, Jianhua District, Qiqihar City

经费或物资来源:

齐齐哈尔医学院重点培育项目

Source(s) of funding:

Qiqihar Medical College key cultivation project

研究疾病:

孤独症谱系障碍  

Target disease:

Autism spectrum disorder

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

单臂 

Study design:

Single arm 

研究目的:

本研究就将基于孤独症患儿体内微量元素及维生素A/D水平进行分组,随后给予为期3个月的复合益生菌干预,检测孤独症患儿的肠道菌群结构及肠道相关神经递质等指标的变化,评估患儿胃肠及行为问题的是否得到改善,期望阐明微量元素及维生素A/D的缺乏是否会影响益生菌对ASD患儿行为及胃肠问题的作用,本研究将为孤独症患儿胃肠问题的治疗提供科学依据。  

Objectives of Study:

In this study, autistic children were divided into groups based on the levels of trace elements and vitamin A/D, and then given compound probiotic intervention for 3 months to detect the changes in gut flora structure and enteric-related neurotransmitters and other indicators of children with autism, and to evaluate whether the gastrointestinal and behavioral problems of autistic children were improved. It is expected to clarify whether the deficiency of trace elements and vitamin A/D will affect the effect of probiotics on the behavior and gastrointestinal problems of ASD children, and this study will provide scientific basis for the treatment of gastrointestinal problems in ASD children.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄3-10周岁,男、女不限; 2. 符合美国精神病学会《精神障碍诊断和统计手册》第五版(DSM-5)关于ASD的诊断标准; 3. 伴有腹泻、便秘、腹胀等胃肠症状; 4. 受试者和(或)监护人签署知情同意书,同意研究者配合临床试验全过程并采集临床资料和外周血、粪便样本。

Inclusion criteria

1. Age 3-10 years old, male and female; 2. Meet the diagnostic criteria for ASD in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); 3. Accompanied by diarrhea, constipation, abdominal distension and other gastrointestinal symptoms; 4. The subject and/or guardian sign informed consent, agreeing to cooperate with the researcher in the whole process of clinical trial and collect clinical data, peripheral blood and fecal samples.

排除标准:

1.明确有脑外伤、脑瘫、脑炎等脑部器质性疾病史;2. 明确诊断为其他精神疾病; 3. 存在肠道器质性病变如先天性巨结肠、肠梗阻、肠套叠等; 4. 存在病理性肠道炎症改变,如炎症性肠病等;5. 近3个月内或在接下来6个月内有计划使用抗生素类影响肠道菌群药物; 6. 近12个月内曾接受过FMT治疗; 7. 近3个月服用过维生素A/D及复合微量元素以及其他相关药物

Exclusion criteria:

1. Having history of brain trauma, cerebral palsy, encephalitis and other organic brain diseases; 2. diagnosed with other mental illness; 3. There are organic intestinal diseases such as hirschsprung's disease, intestinal obstruction, intussusception, etc.; 4. Pathological intestinal inflammatory changes, such as inflammatory bowel disease; 5. In the last 3 months or in the next 6 months, there are plans to use antibiotics that affect the gut flora; 6. Have received FMT treatment within the last 12 months; 7. Have taken vitamin A/D, complex trace elements and other related drugs in the past 3 months.

研究实施时间:

Study execute time:

From 2024-03-15 00:00:00 To 2025-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-03-15 00:00:00 To 2024-03-31 00:00:00

干预措施:

Interventions:

组别:

微量元素或维生素A/D缺乏组

样本量:

20

Group:

Trace element or vitamin A/D deficiency group

Sample size:

干预措施:

复合益生菌

干预措施代码:

Intervention:

complex probiotics

Intervention code:

组别:

微量元素或维生素A/D水平正常组

样本量:

20

Group:

Trace element or vitamin A/D level normal group

Sample size:

干预措施:

复合益生菌

干预措施代码:

Intervention:

complex probiotics

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

黑龙江省 

市(区县):

 

Country:

China

Province:

Heilongjiang

City:

单位(医院):

齐齐哈尔医学院 

单位级别:

大学 

Institution
hospital:

Qiqihar Medical University

Level of the institution:

University

测量指标:

Outcomes:

指标中文名:

肠道菌群

指标类型:

主要指标

Outcome:

gut microbiome

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

微量元素及维生素A和D

指标类型:

主要指标

Outcome:

Trace elements and vitamins A and D

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道相关神经递质

指标类型:

次要指标

Outcome:

Gut-related neurotransmitters

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃肠问题评分

指标类型:

次要指标

Outcome:

Gastrointestinal problem score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

儿童孤独症评定量表

指标类型:

次要指标

Outcome:

Childhood Autism Rating Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

儿童行为量表

指标类型:

次要指标

Outcome:

Child Behavior Checklist

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

faeces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 3 years
最大 Max age 10 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

可通过邮件向研究者索取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Available from the researcher by email

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-03-15 08:42:39